Jahanbakhsh Nasserzare, MD
Psychiatry · North Miami Beach, FLNPI 1164632550
Payments from drug & device makers
Across 494 payments — averaging $46.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuronetics, Inc.$11K
- Teva Pharmaceuticals USA, Inc.$2K
- Neurocrine Biosciences, Inc.$1K
- AbbVie$1K
- Alkermes, Inc.$957
- Almatica Pharma LLC$952
- plus $6K from 18 others
What the payments were for
- Food & beverage$12,19453%
- Education$370%
- Other$10,98047%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuronetics, Inc. | 10 | $11,275 |
| Teva Pharmaceuticals USA, Inc. | 69 | $1,939 |
| Neurocrine Biosciences, Inc. | 52 | $1,325 |
| AbbVie(2 entities) | 48 | $1,145 |
| Alkermes, Inc. | 47 | $957 |
| Almatica Pharma LLC | 44 | $952 |
| Johnson & Johnson | 21 | $920 |
| Sunovion Pharmaceuticals Inc. | 55 | $830 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $679 |
| Otsuka America Pharmaceutical, Inc. | 34 | $650 |
| E.r. Squibb & Sons, L.L.C. | 10 | $443 |
| Axsome Therapeutics, Inc. | 15 | $428 |
| Vanda Pharmaceuticals Inc. | 14 | $403 |
| Lundbeck LLC | 14 | $292 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $291 |
| Bausch Health US, LLC | 10 | $219 |
| Idorsia Pharmaceuticals US Inc | 2 | $133 |
| Indivior Inc. | 4 | $118 |
| Neos Therapeutics, LP | 5 | $94 |
| Avanir Pharmaceuticals, Inc. | 2 | $35 |
| Acadia Pharmaceuticals Inc | 1 | $25 |
| Noven Therapeutics, LLC | 1 | $22 |
| Corium, LLC | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEUROSTAR TMS THERAPY SYSTEM$10,980
- Austedo XR$588
- SPRAVATO$366
- VRAYLAR$250
- AUSTEDO$249
- COBENFY$241
- CAPLYTA$221
- NEUROSTAR TMS THERAPY$181
- REXULTI$122
- QUVIVIQ$119
- UZEDY$119
- Auvelity$112
How this compares
$23,212 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 162 | $1,302,235 |
| Austedo XrDeutetrabenazine | 65 | $708,323 |
| SpravatoEsketamine Hcl | 478 | $603,316 |
| LybalviOlanzapine/Samidorphan Malate | 117 | $193,904 |
| Chlorpromazine Hcl | 394 | $174,855 |
| Abilify MaintenaAripiprazole | 59 | $166,935 |
| Invega SustennaPaliperidone Palmitate | 59 | $139,439 |
| Loreev XrLorazepam | 255 | $117,666 |
| FanaptIloperidone | 42 | $88,793 |
| AustedoDeutetrabenazine | 12 | $64,995 |
| TrintellixVortioxetine Hydrobromide | 109 | $55,638 |
| VraylarCariprazine Hcl | 38 | $55,439 |
| Divalproex Sodium | 1,098 | $54,197 |
| Haloperidol | 783 | $46,551 |
| Quetiapine Fumarate | 1,507 | $41,143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,325 | $1,302,235162 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $1,939 | $773,31977 claims |
| Johnson & JohnsonSpravato, Invega Sustenna | $920 | $742,755537 claims |
| Alkermes, Inc.Lybalvi | $957 | $193,904117 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $650 | $166,93559 claims |
| Almatica Pharma LLCLoreev Xr, Sertraline Hcl | $952 | $125,4441,323 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $403 | $88,79342 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $291 | $55,638109 claims |
| AbbVieVraylar | $1,145 | $55,43938 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in North Miami Beach
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
- Olga LapeyraLauderhill$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.